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Alginate-polylysine microencapsulation allows for
successful transplantation of allo- and xenogenic is-
lets but graft function is still limited [1–6]. Usually,
graft failure is interpreted as the consequence of a
non-specific foreign body reaction against the micro-
capsules resulting in progressive fibrotic overgrowth
of the capsules [5–11] and necrosis of the islets.
Alginate is a polysaccharide composed of man-
nuronic and guluronic acids. Mannuronic acid has
been identified as the major initiator of the foreign
body reaction by some [7], while others found gu-
luronic acid to be associated with more severe fibrotic
overgrowth [8]. Coating of the capsules with addi-
tional layers of alginate has been found to be associ-
ated with less severe fibrotic overgrowth [11] which
suggests a role for polylysine in the initiation of the
foreign body reaction. All these studies, however,
were performed with alginates which had not been
purified.
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Summary Graft failure of alginate-polylysine micro-
encapsulated islets is often interpreted as the conse-
quence of a non-specific foreign body reaction
against the microcapsules, initiated by impurities pre-
sent in crude alginate. The aim of the present study
was to investigate if purification of the alginate im-
proves the biocompatibility of alginate-polylysine mi-
crocapsules. Alginate was purified by filtration, ex-
traction and precipitation. Microcapsules prepared
from crude or purified alginate were implanted in
the peritoneal cavity of normoglycaemic AO-rats
and retrieved at 1, 2, 3, 6, 9, and 12 months after im-
plantation. With crude alginate, all capsules were
overgrown within 1 month after implantation. With
purified alginate, however, the portion of capsules
overgrown was usually less than 10%, even at
12 months after implantation. All recipients of islet
allografts in capsules prepared of purified alginate
became normoglycaemic within 5 days after implan-
tation, but hyperglycaemia reoccurred after 6 to
20 weeks. With intravenous and oral glucose tol-
erance test, all recipients had impaired glucose toler-
ance and insulin responses were virtually absent. Af-
ter graft failure, capsules were retrieved (80–100%)
by peritoneal lavage. Histologically, the percentage
of overgrown capsules was usually less than 10%
and maximally 31%. This small portion cannot ex-
plain the occurrence of graft failure. The immunopro-
tective properties of the capsules were confirmed by
similar if not identical survival times of encapsulated
islet allo- and isografts. Our results show that purifi-
cation of the alginate improves the biocompatibility
of alginate-polylysine microcapsules. Nevertheless,
graft survival was still limited, most probably as a
consequence of a lack of blood supply to the encapsu-
lated islets. [Diabetologia (1997) 40: 262–270]
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Alginate is a crude product extracted from alga
and is contaminated with different inflammation pro-
voking components [12] of which only polyphenols
and endotoxins have been identified. Varying degrees
of purity may explain the controversies in studies ad-
dressing the cause of the bioincompatibility of algi-
nate-poly-L-lysine (PLL) capsules.
The aim of the present study in rats was to investi-
gate the effect of purification of alginates on the bio-
compatibility of alginate-PLL microcapsules. There-
fore, a purification procedure for alginate was devel-
oped. Empty capsules prepared of either crude or pu-
rified alginate were implanted in the peritoneal cav-
ity and retrieved after varying time intervals for his-
tological evaluation of the degree of the fibrotic re-
sponse against the capsule grafts. Furthermore, we
investigated the function of microencapsulated islet
allografts and the capsular overgrowth of encapsu-
lated iso- and allografts when purified alginate was
applied.
Materials and methods
Design of the study. Batches of empty microcapsules were di-
vided into six portions of approximately 2 ml and subsequently
implanted into the peritoneal cavity of six normoglycaemic
AO rats. Of these six rats, one was subjected to peritoneal lav-
age at 1, 2, 3, 6, 9 or 12 months after implantation. Similar vol-
umes of capsules were implanted in Biobreeding (BB)-rats in
order to exclude rat strain dependency of the reaction against
the capsules. From these rats the capsules were retrieved by
peritoneal lavage at 1 month postimplant only.
The total volume of the capsules recovered by peritoneal
lavage was related to the initial volume of the implanted graft.
The number of recovered capsules with fibrotic overgrowth
was assessed by microscopy of histological sections of the cap-
sules. This fraction of overgrown capsules was expressed as
the percentage of the total number of recovered capsules.
Diabetic AO-rats served as recipients of capsules prepared
from purified alginate containing either AO (isografts) or
Lewis-islets (allografts). Islets were cultured before encapsula-
tion in order to reduce contamination of the grafts with exo-
crine tissue, ducts or damaged cells. Graft endocrine volume
was at least 10 ml, which is approximately equal to the endo-
crine volume of the normal rat pancreas [13]. Blood glucose
was determined at regular time intervals. Recipients with
blood glucose levels lower than 8.4 mmol/l were considered
normoglycaemic. One or two weeks after the reoccurrence of
hyperglycaemia, microcapsules were retrieved from the dia-
betic recipients by peritoneal lavage and processed for histo-
logical examination. At 4 to 6 weeks after implantation of suc-
cessful encapsulated islet allografts the rats were provided with
two cardiac catheters implanted via the right and left jugular
vein for blood sampling and infusion of glucose, respectively,
in unanaesthetized and freely moving rats [14, 15]. Subse-
quently, the function of encapsulated islet allografts was tested
by an intravenous glucose tolerance test (IVGTT) and by a
meal test [6, 13]. Normal rats served as controls.
Animals and induction of diabetes. Male inbred Albino Oxford
(AO/G) rats were obtained from the Central Animal Labora-
tory of Groningen, inbred Lewis rats were obtained from
Harlan CPB, Zeist, The Netherlands, and BB/Org-rats were
obtained from the Central Animal Facility of Erasmus Univer-
sity, Rotterdam, The Netherlands.
AO/G-rats and Lewis-rats weighing 300–350 g served as do-
nors. AO/G-rats weighing 290–320 g were used as recipients of
encapsulated islet grafts. Diabetes was induced in these rats by
injection of 75–90 mg/kg of streptozotocin (Zanosar, Upjohn
Co., Kalamazoo, Mich., USA) via the tail vein. A second injec-
tion of 70–90 mg/kg of streptozotocin was administered when
at 10–14 days after the first injection the blood glucose level
was less than 20 mmol/l. Only animals with severe weight loss,
polyuria, polydipsia and fasting blood glucose levels exceeding
20 mmol/l over a period of at least 4 weeks were used as recip-
ients. At the time of peritoneal lavage a biopsy was taken from
the tail of the pancreas. If not mentioned otherwise the rats
had less than 5 % of the normal number of beta cells present
in their pancreas. As shown in one of our previous studies
[16], the circulating insulin levels in these diabetic rats never
exceeded 24 pmol/l.
Islet isolation. Islets were isolated as previously described [17].
Briefly, under ether anaesthesia, the abdomen was opened and
the common bile duct was cannulated under non-sterile condi-
tions. The donor pancreas was distended with 10 ml sterile
Krebs-Ringer-Hepes supplemented with 25 mmol/l Hepes buf-
fer (KRH) and containing 10 % bovine serum albumin (BSA).
Subsequently the pancreas was excised, and brought into a
laminar flow cabinet. All further procedures were performed
under sterile conditions.
The pancreas was chopped, digested using a two-stage incu-
bation of 20 min at 37 ° C with successively 1.0 and 0.7 mg/ml
collagenase (Sigma type XI; Sigma, St. Louis, Mo., USA). Is-
lets were separated from exocrine tissue by centrifugation
over a discontinuous dextran gradient [18] and further purified
by handpicking.
The total islet volume obtained by the isolation procedure
was determined by measuring the diameters [13] of islets in a
4 % aliquot of the islet suspension. Subsequently, the total vol-
ume was calculated, assuming the islets to be perfect spheres.
In each experiment we used four to five donors from which
we isolated a total of 3500–4200 islets which corresponds to
10–15 ml of islet tissue.
The islets were cultured in non-treated petri-dishes (Gre-
iner, Alphen a/d Rijn, The Netherlands) in portions of 100 is-
lets per 25 cm2 for 19 to 44 h in CMRL1066 (containing 10 %
fetal calf serum (FCS, Gibco, Breda, The Netherlands),
8.3 mmol/l glucose and 10 mmol/l Hepes and 1 % penicillium/
streptomycin) at 37 ° C in humidified air containing 5 % CO2.
After this culture period the total islet volume was assessed
again.
The diameter of the islets was measured with a dissection
microscope with a fluorescent illuminator (Bausch and Lomb
BVB-125, and 31–33–66, Rochester, NY, USA) equipped with
an ocular micrometer with an accuracy of 25 mm.
Purification of alginate. Crude sodium alginate (Keltone LV;
Kelco International, London, UK) was dissolved at 4 ° C in a
1 mmol/l sodium EGTA solution to a 1 % solution under con-
stant stirring, and filtered over, successively, 5.0, 1.2, 0.8, and
0.45 mm filters (Schleicher & Schu¨ll, ’s-Hertogenbosch, The
Netherlands). During this filtration step, all visible aggregates
were removed, and the solution lost its original yellow colour
and became translucent.
Next, the pH of the solution was lowered to 3.5 under con-
stant monitoring by addition of 2 N HCl plus 20 mmol/l NaCl.
The solution was kept on ice to prevent hydrolysis of alginate.
The further slow lowering from 3.5 to 1.5 was associated with
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gradual precipitation of alginate as alginic acid (precipitation
curves not shown) [19]. Routinely, the solution was brought at
a pH of 2.0 and subsequently filtered over a Buchner funnel
(pore size 1.5 mm) to wash out non-precipitated contaminants.
To extend the wash-out of non-precipitated contaminants, the
precipitate was brought in 0.01 N HCL plus 20 mmol/l NaCl,
vigorously shaken, and filtered again over the Buchner funnel.
This washing procedure was performed three times.
Then, proteins were removed by extraction with chloro-
form/butanol [20]. The alginic acid was suspended in 100 ml
of 0.01 N HCl plus 20 mmol/l NaCl and supplemented with
20 ml chloroform and 5 ml 1-butanol. The mixture was vigor-
ously shaken for 30 min and filtered over the Buchner funnel.
This chloroform/butanol extraction was performed three
times. Next, the alginic acid was brought in water and slowly
dissolved by gradually raising the pH to 7.0 by the slow addi-
tion of 0.5 N NaOH plus 20 mmol/l NaCl over a period of at
least 1 hour. The alginate solution obtained was subjected to
a chloroform/butanol extraction to remove those proteins
which can only be dissolved in chloroform/butanol at neutral
pH [20]. The solution was vigorously shaken in a mixture of
chloroform (20 ml at each 100 ml alginate solution) and 1-but-
anol (5 ml at each 100 ml alginate solution) for 30 min. The
mixture was centrifuged for 3–5 min at 3000 rev/min, which in-
duced the formation of a separate chloroform/butanol phase
which was removed by aspiration. The extraction was repeated
once.
The final step was precipitation of the alginate with ethanol
[21, 22]. To each 100 ml of alginate solution we added 200 ml
absolute ethanol (Ethylalcohol, absolute; NedAlco, Bergen
op Zoom, The Netherlands). After an incubation period of
10 min all alginate had precipitated. It was filtered over the
Buchner funnel and washed two times with absolute ethanol.
Finally, the alginate was washed three times with ethylether
and freeze-dried overnight.
Usually, the purification run was started with 10 g of algi-
nate of which 6–7.5 g remained at the end of the procedure.
The transplant studies were performed with three different
Keltone LV lot numbers. This purification procedure did not
influence the characteristics of the alginate, since analysis [23,
24] of the composition of the alginate before and after purifica-
tion showed no changes in its guluronic acid and mannuronic
acid content. It was always composed of 40 % guluronic acid
and 60 % mannuronic acid.
Formation of islet-containing and empty capsules. After cul-
ture, islets were washed three to five times with RPMI contain-
ing 10 % FCS and subsequently suspended in sterile filtered
(0.2 mm filtration) 3 % purified alginate solution. The alginate
solution was converted into droplets using an air-driven drop-
let generator as previously described [25]. Polylysine-alginate
encapsulation was performed as described elsewhere [26].
Briefly, the alginate droplets were transformed to alginate
beads by gelling in a 100 mmol/l CaCl2 (10 mmol/l HEPES,
2 mmol/l KCl) solution for at least 5 min. After gelation the
beads had a diameter of 450–550 mm. Subsequently, the Ca-al-
ginate beads were suspended for 1 min in KRH buffer contain-
ing 2.5 mmol/l CaCl2. A PLL membrane was formed by sus-
pending the alginate beads in 0.1 % PLL solution for 10 min
(poly-L-lysine-HCl, Mr: 22000, Sigma). Non-bound PLL was
removed by three successive washings during 3 min with
Ca2 + -free KRH containing 135 mmol/l NaCl. The outer algi-
nate-layer was subsequently applied by 5 min incubation in 10
times diluted alginate solution. In order to liquify their inner
cores, the microcapsules were suspended in 1 mmol/l EGTA
in Ca2 + -free KRH for 10 min, and washed three times with
KRH containing 2.5 mmol/l CaCl2. Finally, the capsules had a
diameter of 600–700 mm and were impermeable for substances
larger than 100 kDa, as measured by diffusion into the capsules
of lectins with varying molecular weights [27].
Viability of the islet tissue before transplantation was con-
firmed in the majority of the experiments by applying the acri-
dine orange (Sigma)/propidium iodide (Sigma) viability assay
[28] on portions of 20–100 islet-containing capsules. We always
found more than 85 % of the islet tissue to be vital.
Implantation and explantation of islet containing and empty
capsules. Under ether anaesthesia, the microencapsulated is-
lets or empty capsules were injected into the peritoneal cavity
with a 16 gauge cannula via a small incision (3 mm) in the linea
alba. The abdomen was closed with a two-layer suture. The im-
planted volumes varied between 1.5 and 2.5 ml.
Peritoneal lavage was performed by infusing 20 ml KRH
through a 3-cm midline incision into the peritoneal cavity and
subsequent flushing of the abdomen above a 50 ml centrifuge
tube. The abdominal organs were flushed two to three times
with KRH.
Glucose tolerance tests. IVGTTs were performed by infusion of
200 mg glucose at a rate of 10 mg/min. The meal tests were car-
ried out by offering the animal 2 g rat chow (containing 53 %
carbohydrate, 20 % protein, 5 % fat and 22 % other constitu-
ents [minerals, cellulose, water]), mixed with 2 ml water. The
animals had been habituated to consume the meal within
5 min.
In both tests, blood samples were taken at 10 min and im-
mediately before the start of the tests, and at 1, 3, 5, 7, 10,
15, 20, 25, 30, 45, 60, 75, 90, 105, and 120 min after the start
of the tests. Blood lost during sampling was replaced by trans-
fusing blood from normal donor rats after every blood sam-
ple.
In some recipients, glucose tolerance could not or not com-
pletely be tested as a consequence of technical complications
such as death related to cannulation surgery or occlusion of
the catheters, or refusal to eat more than 70 % of the test
meal.
Chemical determinations. Glucose concentrations during the
glucose tolerance testing were determined in whole blood by
a ferricyanide method with a Technicon autoanalyser. The glu-
cose concentration in blood obtained at weekly intervals was
determined with glucose test tapes (Reflolux; Boeringer
Mannheim, Mannheim, FRG). Plasma insulin was measured
by a radioimmunoassay (Linco, Rat Insulin Ria Kit, St.
Charles, MO, USA). Glycosylated hemoglobulin was mea-
sured by applying an affinity based chromatography assay
(Glyc-Affin GHB, ISOLABinc., Ohio, USA).
Histology and immunohistochemistry of recovered material.
Half of the volume of recovered capsules and biopsies of cap-
sules stuck to abdominal organs were fixed in pre-cooled 2 %
paraformaldehyde, buffered with 0.05 mol/l phosphate, and
processed for glycol methacrylate embedding [29]. Sections
were prepared at 2 mm, stained with Romanovsky-Giemsa
stain, and applied to assess the degree of capsular overgrowth,
which was quantified by expressing the number of recovered
capsules with overgrowth as the percentage of the total num-
ber of recovered capsules.
The other half of recovered microcapsules and the pancreas
biopsies were fixed in Bouin’s solution for paraffin processing,
sectioned at 5 mm, and stained with aldehyde fuchsin. In these
sections, the presence or absence of viable beta cells was deter-
mined.
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Statistical analysis. Statistical evaluation was performed using
the Mann Whitney U test. Values are expressed as mean –
SEM. Only p values less than 0.05 were considered to indicate
a statistically significant difference.
Results
Empty capsules prepared from crude and purified alg-
inate. Within 1 month post-implant, all empty cap-
sules prepared of crude alginates were overgrown by
fibrotic tissue and surrounded by collagen deposits
(Fig. 1). The capsules were found to be adherent to
the omentum and the liver capsule. Up to 18 months
after implantation, we still found capsules at these
sites, and found no indications of biodegradability of
the capsules.
Occasionally, we found a portion of the empty cap-
sules prepared from purified alginate to be adherent
to the omentum and the liver capsule. The majority
of capsules, however, was freely floating in the ab-
dominal cavity without adhesion to the abdominal or-
gans. The free capsules could readily be flushed out of
the peritoneal cavity, resulting in an explantation of
80–100% up to 1 year post-implant (Fig. 2). Of these
recovered capsules, the mean percentage of capsules
with overgrowth remained usually well below 10%
with monthly assessments during the year. There was
one exception at 3 months post-implant (12.6 – 9 %)
as the consequence of one single recipient with 30%
overgrowth.
In histological sections of explants we recurrently
observed that some capsules contained defects which
were surrounded by immune cell elements with the
morphological appearance of macrophages (Fig. 3).
This cellular infiltration of defect capsules, however,
was a temporary phenomenon since after 2 months
only overgrowth composed of several layers of fibro-
blasts surrounding the capsule was observed.
One series of 6 animals was excluded from the
study since a severe inflammatory reaction had oc-
curred resulting in sepsis and death of two recipients.
This inflammatory reaction was induced by bacterial
contamination of the purified alginate.
In order to exclude that the mild reaction towards
the capsules prepared from purified alginate is spe-
cific for the AO-rat strain we also implanted empty
capsules in the peritoneal cavity of four prediabetic
BB-rats which reportedly are high responders toward
alginate-PLL capsules [4, 8]. Also in the BB-rats,
1 month after implantation, we observed the majority
of capsules to be freely floating in the peritoneal cav-
ity. By peritoneal lavage 79 – 9% of the capsules
could be retrieved of which a portion of 9.3 – 0.9%
was overgrown by fibrotic tissue.
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Fig. 1. Alginate-polylysine capsules prepared of crude algi-
nate, 1 month after implantation. The capsules are adherent
to the omentum. (GMA-embedded histological section, Syr-
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Fig. 2. Percentage capsules explanted (U) and overgrown by
fibrotic tissue (k). Capsules were prepared of purified algi-
nates and implanted in the peritoneal cavity of normoglycae-
mic AO-rats. Every time point represents the average of the
results obtained in four animals
Fig. 3. Empty alginate-polylysine capsule prepared from puri-
fied alginate, 1 month after implantation. The capsule contains
a defect and is overgrown by macrophages. (GMA-embedded
histological section, Romanowsky-Giemsa stain, original mag-
nification · 150)
Islet allografts encapsulated with purified alginate.
Transplantation of encapsulated islets was restricted
to experiments with purified alginate since in a previ-
ous study [27] we found that fibrotic responses similar
to that observed against the crude alginate were al-
ways associated with early graft failure.
Streptozotocin diabetic AO recipients of allogenic
islets encapsulated in purified alginate became nor-
moglycaemic in 10 out of 13 cases. The 10 successfully
transplanted rats became normoglycaemic within
5 days after implantation and remained normogly-
caemic for 6 to 20 weeks (Fig. 4). As shown in our pre-
vious study, AO recipients never became normogly-
caemic after transplantation of 10 ml of non-encapsu-
lated Lewis islet tissue [6].
Prior to glucose tolerance tests, basal insulin lev-
els in recipients of microencapsulated islet allografts
were much lower than in normal control rats. These
low insulin levels did not correspond with the con-
comitant basal glucose levels which were found to
be similar in recipients and control rats (Fig. 5). The
glucose challenge did not initiate an elevation of
plasma insulin in rats with microencapsulated islets,
while normal control rats had a clear insulin re-
sponse during both the IVGTT and the meal test.
The concomitant glucose levels in recipients of en-
capsulated islet allografts reached higher levels and
returned more slowly to basal levels than in normal
control rats.
The results of the meal tests in two recipients were
excluded from the calculations of the mean since
these two recipients, unlike the other recipients,
showed disparate results with intravenous and oral
glucose challenge. Their response to IVGTTwas sim-
ilar to that of other recipients. But with meal tests 1
week later, we observed much higher peak glucose
levels and no re-establishment of basal glucose levels
during the test, in spite of normoglycaemic basal glu-
cose levels and regular insulin levels prior to the test.
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Fig. 4. Non-fasting blood glucose concentrations in streptozo-
tocin diabetic AO-rats (n = 10) after implantation of islet allo-
grafts microencapsulated in capsules prepared of purified algi-
nate. (—) animals returning to hyperglycaemia, + , animals
which died of a technical complication, * animals with 5–10 %
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Fig. 5 A, B. Blood glucose and plasma insulin levels after in-
travenous glucose infusion (10 mg/min) (n = 4) (A) and after
spontaneous ingestion of a meal (n = 5) (B) in AO- recipients
of microencapsulated islet allografts (U) and in normal con-
trol rats (k)
After another week, both animals had completely
returned to hyperglycaemia with elevated basal glu-
cose levels.
In spite of disturbed glucose tolerance during the
glucose challenge, we found in all successfully trans-
planted recipients, the percentage glycosylated
haemoglobulin to be reduced from a pretransplant le-
vel of 10.4 – 1.2 % to 4.6 – 0.4 % within 3 weeks after
transplantation. This post-transplant glycosylated
haemoglobulin percentage was not significantly dif-
ferent from the percentage glycosylated haemoglob-
ulin in control rats, which was 4.3 – 0.1%.
Histology of islet allografts encapsulated with purified
alginate. Two recipients were normoglycaemic when
they died 6 and 8 weeks after transplantation
(Fig. 4). From these two, we could retrieve 60 and
100% of the capsules, 2 and 31% of which were over-
grown by fibrous tissue, respectively. The microcap-
sules were found to contain many viable islets stain-
ing positive for insulin. The islets, however, had smal-
ler diameters than before transplantation as indicated
by the presence of an alginate free ring around the
encapsulated islets (Fig. 6.A).
The other eight recipients were killed approxi-
mately 1 or 2 weeks after the reoccurrence of hyper-
glycemia. In these animals, the majority of capsules
was found to be freely floating in the peritoneal cav-
ity without any cellular adhesion. The portion of
overgrown capsules in these eight recipients was al-
ways similar or even smaller than the portion of over-
grown capsules found in the other two (Table 1).
There was no relation between the duration of graft
function and the number of capsules overgrown by
fibrotic tissue. After graft failure we found non-
overgrown capsules with non-viable islet remnants.
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A B
Fig. 6 A, B. Alginate-polylysine encapsulated islet, after allo-
transplantation. (A) An example of an islet surrounded by an
alginate free ring, 4 weeks after implantation (paraffin-embed-
ded histological section, Aldehyde-fuchsin stain, original mag-
nification · 100). AP, alginate polylysine; AF, alginate free
zone; A, alginate. (B) An islet positively stained for insulin,
14 weeks after transplantation (GMA-embedded histological
section, original magnification · 200). Arrow indicates ne-
crotic zone
Table 1. Recovery rates and percentage of capsules with overgrowth at varying time intervals after implantation of microencapsu-
lated rat allografts in streptozotocin diabetic AO-rats
Time (weeks) between implantation
and peritoneal lavagea
State of glycaemia immediately
preceding peritoneal lavagea
Percentage of retrieval Percentage of capsules
with overgrowth
6b normo 60 2
8b normo 100 31
6 hyper 90 3
7 hyper 75 14
8 hyper 100 6
12 hyper 90 9
12 hyper 80 1
13 hyper 100 8
17 hyper 70 30
20 hyper 100 1
a Peritoneal lavage was performed immediately after death in
the two animals that died normoglycaemic of a technical com-
plication (b). In the other eight recipients it was performed
approximately 1 or 2 weeks after reoccurrence of hyperglycae-
mia.
b Died accidentally of a technical complication
Occasionally, we found some viable islets with large
necrotic zones (Fig. 6.B).
Islet isografts encapsulated with purified alginate. In
order to exclude that an immune response against
the allogeneic islets in the capsules was the cause of
the limited graft function we transplanted encapsu-
lated islets isogenically in diabetic AO-rats. Six of
eight recipients became normoglycaemic. The recipi-
ents of successful isografts showed individual graft
survival times quite similar to recipients of allografts
(Fig. 7). As shown in Table 2, not only the mean graft
survival was similar with encapsulated iso- and allo-
grafts, but also the percentage of capsules retrievable
by peritoneal lavage and the portion of overgrown
capsules. After graft failure the islets in the non-over-
grown capsules had a necrotic appearance similar to
that observed in allografted encapsulated islets.
Discussion
This study evaluates the effect of a multi-step alginate
purification procedure principally composed of filtra-
tion, precipitation, and subsequent protein extrac-
tion. This evaluation was not performed by testing
the purity of alginate with physical or chemical meth-
ods, since it is not known which contaminants are re-
sponsible for the reaction against capsules prepared
of crude alginate, nor which grade of purity is re-
quired to obtain biocompatible capsules. Therefore,
we have rather evaluated the effect of purification
by assessing the responses to empty and islet contain-
ing capsules implanted in the peritoneal cavity of rats.
This is the first study to demonstrate that purifica-
tion of alginate improves the biocompatibility of algi-
nate-PLL capsules. Nevertheless, even with purified
alginate, a small portion of the capsules was always
found to be overgrown by fibrous tissue. This indi-
cates that bioincompatibility is influenced not only
by the chemical composition but also by individual
imperfections of capsules. This is corroborated by
our observation that some capsules contain localized
defects [30, 31].
Islet allografts encapsulated in capsules prepared
from purified alginate could successfully be trans-
planted into streptozotocin diabetic AO-rats. How-
ever, the graft function was of limited duration. This
limited graft function was not caused by insufficient
immunoprotection of the allogenic tissue since allo-
and isografts had similar graft survival rates. Neither
can it be explained by fibrosis of the capsules since
the percentage of capsules overgrown was 30% at
maximum and usually below 10%, both in function-
ing and non-functioning grafts.
One may hypothesize that cytokines released dur-
ing the cascade of the fibrotic reaction against a small
percentage of the capsules can be held responsible for
damaging not only the islets in these capsules but also
those contained by the other, intact, capsules, thereby
inducing graft failure. This, however, is unlikely since
we found high numbers of well granulated and intact
islets without signs of cytotoxic damage in still nor-
moglycaemic animals 1 month after implantation. At
this time, the capsular reaction was completed since
an increase was not observed during the following
months (Fig. 1). Also, we would have expected a
more severe fibrotic reaction to be associated with a
shorter duration of graft function, but such an associ-
ation was not observed (Table 1).
The phenomenon of graft failure in the absence of
overgrowth of the capsules has been reported previ-
ously [1, 32, 33] and is explained by exhaustion of
the graft as a consequence of an insufficient number
of transplanted encapsulated islets in relation to the
glycaemic load. This too, however, appears unlikely
to explain the limited graft survival in our study since
we transplanted a sufficient islet volume of 10 ml,
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Fig. 7. Non-fasting blood glucose concentrations in streptozo-
tocin diabetic AO-rats (n = 6) after implantation of microen-
capsulated islet isograft. (–– –) animals returning to hypergly-
caemia, * animals with 5–10 % vital beta cells in their native
pancreas. Values represent mean – SEM
Table 2. Weeks of graft survival, implanted islet volume, recovery rates and percentage of capsules with overgrowth after implan-











Isograft 6 11.7 – 1.8 11.8 – 0.8 82.0 – 8.1 10.7 – 1.9
Allograft 10 12.0 – 1.6a 11.5 – 0.4 86.1 – 4.7 10.5 – 3.6
a Two recipients which died of technical complications were excluded
which is equivalent to the volume of islets present in
the normal pancreas. Another discrepancy which
does not corroborate the explanation of exhaustion
is that glucose levels in the peritoneal fluid are ap-
proximately 80 % of the ambient intravenous levels
[34]. Since the mean of maximum blood glucose con-
centrations in response to a physiological challenge
like a meal is 8.8 – 0.4 mmol/l, encapsulated islets in
the peritoneal cavity are exposed to a maximum glu-
cose level of approximately 7.0 mmol/l, which cannot
induce exhaustion.
The main factor responsible for the limited dura-
tion of encapsulated graft function appears to be
that the lifespan of encapsulated islets is limited by
the presence of the capsule as such, in combination
with the intraperitoneal transplantation site. This is
quite plausible since a successful transplant of 5 ml
non-encapsulated islets under the kidney capsule in-
duces permanent normoglycaemia [13], while suc-
cessful encapsulated islet grafts do not.
If successful, non-encapsulated islets will become
completely vascularized after implantation, but mi-
croencapsulated islets stay unattached and freely
floating in the peritoneal cavity without any vascular
connection. This implies that the supply of nutrients,
growth factors and substancesessential for the homeo-
stasis of islet cells depends upon diffusion from blood
to the peritoneal cavity [35] while it may also be de-
layed by the capsule membrane. Some substances like
transferrin may even be retained as the consequence
of its incompatible conformation or its large molecular
weight. Furthermore, the low oxygen tension [36–38]
and low concentrations of essential minerals [36–39]
in the peritoneal fluid may also contribute to a gradual
decrease of the size of the islet graft and, therefore,
limit the lifespan of the graft. The significance of the
lack of vascular access for the viability of the encapsu-
lated islets and for the occurrence of graft failure is il-
lustrated by our observations that the diameters of en-
capsulated islets become smaller with time and that is-
lets gradually develop necrotic zones.
Not only lifespan limitations of encapsulated islet
grafts but also their functional limitation may to a
large extent be explained by the presence of the cap-
sules as such in combination with the intraperitoneal
transplantation site. When diabetic AO-recipients of
10 ml of intraperitoneal but non-encapsulated islet
isografts were tested at 4 to 6 weeks after transplanta-
tion that is after revascularization of the graft, almost
normal glucose tolerance and clearcut insulin re-
sponses were found [40]. But with successful encapsu-
lated islet grafts such revascularization is lacking and,
consequently, the insulin response depends on the
transfer of glucose and insulin between the peritoneal
fluid and blood. As we previously showed, this trans-
fer is a rather slow process [35] which, together with
the barrier effect of the microcapsule, predictably
results in strongly delayed responses of plasma
insulin and glucose levels when compared to re-
sponses by vascularized islets.
Two recipients showed higher peak levels and a
longer duration of hyperglycaemia than the other
five recipients. This cannot be explained by dimin-
ished insulin secretion by the encapsulated islet graft
as, remarkably, insulin levels in these two recipients
were similar to insulin levels in the other five recipi-
ents (Fig. 3). Our findings rather suggest insulin in-
sensitivity to have developed in these two animals.
Although purification of alginate improves the
biocompatibility of alginate-PLL capsules and there-
by deletes one of the major obstacles in the clinical
applicability of microencapsulated islets, the problem
of limited graft survival remains to be solved. Possible
approaches in order to prolong the function of the
graft may be transplantation of larger quantities of is-
lets [6], co-encapsulation of cells producing growth
factors [41], or transplantation of islets into sites bet-
ter vascularized than the unmodified peritoneal cav-
ity warranting adequate supply of nutrients and
growth factors.
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